This study aimed at examining the cardioprotective effects of resveratrol in rats with simultaneous type 2 diabetes and renal hypertension. Eight groups (8-10 each) of male Sprague-Dawley rats, including a control, a diabetic, a renal hypertensive, a sham, a simultaneously hypertensive-diabetic receiving vehicle, and 3 simultaneously hypertensive-diabetic receiving resveratrol at 5, 10 or 20 mg/kg/day were used. After 4 weeks of treatment, blood pressure and glucose, and serum markers of oxidative stress were measured, and animals' hearts were used for isolated studies. Resveratrol prevented the increase of systolic blood pressure, serum malondialdehyde, fasting blood glucose, infarct size, coronary resistance, and coronary effluent creatine kinase-MB. Moreover, it prevented the decrease of serum superoxide dismutase and glutathione reductase, heart rate, left ventricular developed pressure, rate of increase of ventricular pressure, and rate of decrease of ventricular pressure. In conclusion, our findings show that resveratrol alleviates cardiac dysfunction in diabetic-hypertensive rats by virtue of antioxidant, antihypertensive, and coronary vasodilating activities.
The beneficial cardiovascular effects of red grape juice have been attributed to certain polyphenols such as resveratrol [1] . Resveratrol has been shown to have beneficial cardiovascular and antidiabetic effects. It protected the heart from ischemia-reperfusion injuries as evidenced by reduction of myocardial infarct size [2] . It also improved post-ischemic ventricular function recovery in ex vivo studies on hearts from spontaneously hypertensive rats [3] , and in in vivo studies [4] . Moreover, it reduced the blood pressure of spontaneously [1] and partially nephrectomized [5] hypertensive rats. Furthermore, it caused dilation of precontracted aortic segments from spontaneously hypertensive rats [1] . In addition, it decreased blood glucose in streptozotocin-nicotinamide [6] and streptozotocin [7] -induced diabetes.
The beneficial cardiovascular and antidiabetic effects of resveratrol have been attributed to increased release of nitric oxide (NO) and endothelium-dependent relaxation [5] . It has also been related to the decrease of sympathetic activity [8] , preservation of beta cells [9] , increase of insulin release [6] , enhancement of insulin sensitivity [7] , and decrease of oxidative stress [6] .
Concurrent occurrence of diabetes and hypertension is frequently seen in humans. Given such a widespread concurrence, and the beneficial cardioprotective and antidiabetic effects of resveratrol, the present study was conducted to examine its effects in rats with simultaneous renal hypertension and type 2 diabetes.
The systolic blood pressure (SBP) as well as the concentrations of fasting blood glucose (FBG), serum malondialdehyde (MDA), and coronary artery effluent creatine kinase-MB (CK-MB) of the simultaneous type 2 diabetes and renal hypertensive group treated with vehicle (DM+HTN-V) were significantly higher than those of the vehicle-treated sham group for renal hypertensive rats (Sham-V) and vehicle-treated diabetic control groups (DMC-V) ( Table 1) . The SBP as well as the concentrations of FBG, serum MDA, and coronary artery effluent CK-MB of the simultaneous type 2 diabetes and renal hypertensive groups treated with resveratrol at 5 mg/kg/day (DM+HTN-R5), 10 mg/kg/day (DM+HTN-R10), and 20 mg/kg/day (DM+HTN-R20) were significantly lower than those of the DM+HTN-V group (Table 1) . Moreover, serum levels of superoxide dismutase (SOD) and glutathione reductase (GR) of the DM+HTN-V group were significantly lower than those of the DMC-V and Sham-V groups. Serum levels of SOD and GR of the resveratrol-treated groups were significantly higher than those of the DM+HTN-V group (Table 1) .
Pre-ischemia left ventricular developed pressure (LVDP) and heart rate (HR) of the DM+HTN-V group were significantly lower than those of the DMC-V and Sham-V groups ( Figure 1A & B) . The LVDP and HR of the resveratrol-treated groups were significantly higher than those of the DM+HTN-V group. A similar pattern of differences was found at 30 and 60 minutes of reperfusion ( Figure  1A Pre-ischemia rates of rise (+dp/dt) and decrease (-dp/dt) of left ventricular pressure of the DM+HTN-V group were significantly lower than those of the DMC-V and Sham-V groups (Figure 2A & B). Pre-ischemia +dp/dt and -dp/dt of the resveratrol-treated groups were significantly higher than those of the DM+HTN-V group. A similar pattern of differences was found at 30 and 60 minutes of reperfusion (Figure 2A& B ).
Pre-ischemia coronary resistance (CR) of the DM+HTN-V group was significantly higher than those of the DMC-V and Sham-V groups ( Figure 3A ). Pre-ischemic CRs of the resveratrol-treated groups were significantly lower than that of the DM+HTN-V group. A similar pattern of differences was found at 30 and 60 minutes of reperfusion. The infarct size of the DM+HTN-V group was NPC Natural Product Communications 2015 Vol. 10 No. 2 335 -338 
12±0.81 Δ Abbreviations; a SBP; systolic blood pressure, b FBG; fasting blood glucose, c MDA; malondialdehyde, d SOD; superoxide dismutase, e GR; glutathione reductase, f CK-MB; creatine kinase MB, DMC-V; diabetic control group receiving vehicle, DM-V; diabetic group receiving vehicle, Sham-V; sham-operated group receiving vehicle, HTN-V; hypertensive group receiving vehicle, DM-HTN-V; simultaneously diabetic hypertensive group receiving vehicle, DM+HTN-R5; simultaneously diabetic hypertensive group receiving resveratrol at 5 mg/kg/day, DM+HTN-R10; simultaneously diabetic hypertensive group receiving resveratrol at 10 mg/kg/day, DM+HTN-R20; simultaneously diabetic hypertensive group receiving resveratrol at 20 mg/kg/day. *Significant difference (P≤0.05) from the DMC-V and Sham-V groups. ∆ Significant difference (P≤0.05) from the DM+HTN-V group. significantly higher than those of the DMC-V and Sham-V groups ( Figure 3B ). The infarct sizes of the resveratrol-treated groups were significantly lower than that of the DM+HTN-V group ( Figure 3B ).
The present study showed that simultaneity of renal hypertension and type 2 diabetes was associated with impaired cardiac function characterized by lower indices of cardiac force (LVDP), contractility (+dp/dt), relaxation (-dp/dt), flow (CR), rate (HR), and infarct area. Our findings, on the whole or in part, are similar to those of an our earlier report [10] and those of others [11] . The mechanism of cardiac impairment in the present model is not clear. However, it may be due to diabetes-induced disturbances in Na + /H + or Na + /Ca 2+ exchanger [12] , or calcium ion hemostasis [13] . Moreover, it may be due to long-term hyperglycemia [14] , or increased oxidative stress and apoptosis in myocardial cells [15] . In order to examine the role of oxidative stress in the cardiac impairment, we measured serum levels of MDA, SOD and GR. Our findings indicate that the model was associated with increased level of oxidative stress. Therefore, it might be possible to suggest that, in agreement with previous studies [16] , increased oxidative stress may partly explain the cardiac impairment in the present model.
As far as the literature is concerned, this is the first study to examine the effects of resveratrol on cardiac functions in rats with simultaneous type 2 diabetes mellitus and renal hypertension. The study showed that resveratrol alleviated cardiac dysfunction by preventing the decrease of HR, LVDP, +dp/dt and -dp/dt, and the increase of CR, myocardial infarct size and coronary effluent CK-MB. These findings are similar to those reported on the effects of resveratrol in ischemia reperfusion studies on hearts from normal [2] , diabetic [11] and hypertensive [3] rats. Moreover, our findings are in agreement with those of previous studies that resveratrol significantly improved the LVDP and +dp/dt [11] , attenuated the increase of LVEDP [11] , and reduced myocardial infarct size [3] .
Various mechanisms have been suggested to account for resveratrol's cardioprotection. It has been attributed to resveratrol's ability to inhibit the synthesis and release of pro-inflammatory mediators [17] as well as to prevent endothelial disruption during ischemia reperfusion [3] , scavenge free radicals and offer antioxidant effects [6] , activate ATP-sensitive potassium channels [18] , and decrease apoptosis [19] . In order to examine the possible role of oxidative stress in resveratrol's cardioprotection, serum levels of MDA, SOD and GR were measured in the present study. Our findings show that administration of resveratrol alleviated the oxidative stress in rats with simultaneous type 2 diabetes and renal hypertension. Therefore, we might be in a position to suggest that, in agreement with previous suggestions [3] , the antioxidative stress activity of resveratrol may partly explain its cardioprotective effect. By virtue of antioxidant activity, resveratrol may have directly or indirectly scavenged free radicals [20] , reduced malonaldehyde formation [21] , and increased NO synthesis [1] . Other possible reason for resveratrol's cardioprotection may be its ability to decrease the blood pressure [1] .
Our findings show that, in agreement with previous studies, resveratrol alleviated the increase of blood pressure, which might be due to the enhancement of endothelial NO release [5] , as well as sympathoplegic [8] and antioxidative [22] activities. The alleviation of blood pressure increase results in a lower arterial resistance and afterload, which can decrease the cardiac workload, and thereby attenuate the cardiac dysfunction. Moreover, part of resveratrol's cardioprotection may be attributed to its ability to prevent the increase of coronary resistance. The lower coronary resistance may have led to increased cardiac blood flow, nutrients, and oxygen, all of which can contribute to resveratrol's alleviation of cardiac dysfunction.
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Experimental
General: Ketamine, xylazine and thiopental sodium were obtained from Pan Pharam (Trittau, Schleswig Holstein, Germany), Alfasan (Woerden, The Netherland), and Biochem GmbH (Vienna, Australia), respectively. Heparin and penicillin G were purchased from Leopharma (Ngee Ann, Denmark) and Jaber Ebne Hayyan (Tehran, Iran), respectively. Nicotinamide and carboxymethyl cellulose were purchased from Sigma-Aldrich Chemical Co. (Steinheim, Germany). Streptozotocin and resveratrol were obtained from Teva Parenteral Medicine Inc. (Irvine, CA, USA) and Serva Co (Tulsa, Oklahoma, USA), respectively. Streptozotocin and nicotinamide were dissolved in normal saline, and resveratrol in 0.5% carboxymethyl cellulose. The kit for the measurement of serum MDA was obtained from Bioassay Technology Laboratory (Shanghai, China). Kits for the measurement of serum SOD and GR were obtained from Biorexfars Chemical Kits (Shiraz, Iran). The kit for the measurement of coronary effluent CK-MB was purchased from Pars Azmun Co. (Tehran, Iran). The glucometer for the measurement of FBG was obtained from Accu-check® active (Roche Diagnostics GmbH, Mannheim, Germany). The tail-cuff apparatus (Chart of 5.0 software, PowerLab 4/30) for the measurement of SBP was obtained from ADInstruments Inc. (MA, Sydney, Australia). Langendorff apparatus (ADInstruments, model: LE05200) obtained from PanLab (Barcelona, Spain) was used for isolated heart studies.
Animals:
Male Sprague-Dawley rats (n=80, 200-250 g) were obtained from the Laboratory Animal Breeding Centre, Shiraz University of Medical Sciences, Shiraz, Iran, and kept under standard conditions with rat chow and water ad libitum. All procedures were approved by the University Committee for Care and Use of Animals.
Induction of type 2 diabetes and renal hypertension:
Type 2 diabetes and renal hypertension were induced and confirmed as previously described [16] . Four weeks after the induction of diabetes, the control and type 2 diabetic animals were subjected to sham-operation or induction of two-kidney, one-clip renal hypertension by placing self-made solid plexiglass clips on the left renal arteries, as previously described [16] .
Starting from the day after the operations, 8 groups (n=8-10 each) of animals emerged: DMC-V, Sham-V, HTN-V, DM-V, DM+HTN-V, DM+HTN-R5, DM+HTN-R10, and DM+HTN-R20. Either vehicle or resveratrol was administered by oral gavage for the next 4 weeks. On day 28, SBP and FBG were measured, and the animals were anesthetized using sodium thiopental (70 mg/kg). Blood samples were collected for the measurement of serum levels of MDA, SOD, and GR, and the animals' hearts were used for isolated heart (Langendorff) studies [16] .
